Federated Hermes’s X4 Pharmaceuticals XFOR Stock Holding History

Federated Hermes’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-149	Closed	-$283	–	2252
2025 Q2	$283	Buy	+149	New	+$610	﹤0.01%	2042
2022 Q2	–	Sell	-5	Closed	-$1K	–	2299
2022 Q1	$1K	Buy	+5	New	+$287	﹤0.01%	2129
2020 Q4	–	Sell	-2	Closed	-$1K	–	2345
2020 Q3	$1K	Sell	2 -2	-50%	-$479	﹤0.01%	2202
2020 Q2	$1K	Buy	+4	New	+$1.09K	﹤0.01%	2181
2020 Q1	–	Hold	0	–	-$1K	–	2364
2019 Q4	–	Hold	0	–	–	–	2152
2019 Q2	–	Sell	-2,286	Closed	-$1.19M	–	2230
2019 Q1	$1.19M	Hold	2,286	–	–	﹤0.01%	1246
2018 Q4	$954K	Buy	+2,286	New	+$872K	﹤0.01%	1301

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes's XFOR Position: Q3 2025 in Review

Federated Hermes sold out of X4 Pharmaceuticals (XFOR) in Q3 2025, closing a stake of 149 shares — an estimated $283 sold.

Federated Hermes first reported a position in XFOR in Q4 2018 and held it in 6 quarters. The position peaked at $1.19M in Q1 2019. 42 funds tracked by Wall St. Rank hold XFOR as of Q3 2025.

Federated Hermes reported no remaining X4 Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Federated Hermes sold 149 X4 Pharmaceuticals shares in Q3 2025, an estimated $283.
Federated Hermes first reported a position in X4 Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Federated Hermes's X4 Pharmaceuticals position peaked at $1.19M in Q1 2019.
42 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.